Masimo of Irvine announced today that a studied conducted by the National Institutes of Health (NIH) indicates that its product SpCO may provide a noninvasive measure of acute asthma severity in children.
The study, conducted in the Emergency Department of Monroe Carell Jr. Children's Hospital at Vanderbilt, in Nashville, Tenn., shows that the Masimo Rainbow SET Pulse CO Oximetry (SpCO) may help clinicians better assess asthma severity because it provides a noninvasive means to measure carbon monoxide in the blood.
The study was funded by the NIH and presented at the Pediatric Academy Societies (PAS) annual meeting on May 5.
Asthma is a life-threatening inflammatory disease of the airways that affects more than 6 million children in the United States leading to more pediatric hospitalizations than any other cause.
May is Huntington's Disease Awareness month
UC Irvine Medical Center lands stroke receiving center designation
'OC METRO Minute,' May 7: UCI Medical Center receives $21 million gift from estate of M.A. Douglas
Aliso Viejo-based Clarient's revenue jumps 41 percent
Aliso Viejo's Valeant sees 17 percent uptick in revenue